Financial health
- Operating income covered interest expense -41.1× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$117M | — | — | -$101M | — | $50M |
| 2024 | — | -$55M | — | — | -$49M | — | $173M |
| 2023 | — | -$100M | — | — | -$25M | — | $82M |
| 2022 | — | -$24M | — | — | -$18M | — | $20M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Apr '26 | — | -$30M | — | — | -$31M | — | $30M |
| Jan '26 | — | -$30M | — | — | -$29M | — | $37M |
| Oct '25 | — | -$38M | — | — | -$25M | — | $50M |
| Jul '25 | — | -$29M | — | — | -$26M | — | $33M |
| Apr '25 | — | -$26M | — | — | -$23M | — | $58M |
| Jan '25 | — | -$25M | — | — | -$26M | — | $62M |
| Oct '24 | — | -$15M | — | — | -$20M | — | $173M |
| Jul '24 | — | -$14M | — | — | -$7M | — | $258M |
| Apr '24 | — | -$15M | — | — | -$14M | — | $265M |
| Jan '24 | — | -$11M | — | — | -$8M | — | $86M |
| Oct '23 | — | -$82M | — | — | -$7M | — | $82M |
| Jul '23 | — | -$5M | — | — | -$7M | — | — |
| Apr '23 | — | -$5M | — | — | -$4M | — | — |
| Jan '23 | — | -$7M | — | — | -$6M | — | — |
See the revenue and net-income charts above for enGene Therapeutics Inc.'s multi-year trend.
As of FY2025, enGene Therapeutics Inc. reported — of total debt against $50M of cash; operating income covered interest expense -41.1×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.